Screener
Phathom Pharmaceuticals, Inc. PHAT Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $84.72M+71.1% | $74.27M+88.0% | $58.3M+104% | $57.58M+94.1% | $49.5M+203% | ||
| $18.37M+197% | $15.1M+200% | $12M+222% | $7.65M+100% | $6.19M+163% | ||
| $66.36M+53.2% | $59.18M+71.7% | $46.31M+86.8% | $49.94M+93.2% | $43.31M+209% | ||
| 78.3%-9.2pp | 79.7%-7.6pp | 79.4%-7.5pp | 86.7%-0.4pp | 87.5%+1.9pp | ||
| $8.75M+24.4% | $7.81M-13.9% | $7.77M-15.4% | $7.49M-12.7% | $7.03M-19.2% | ||
| $57.7M+11.9% | $55.33M-35.1% | $54.01M-42.8% | $48.37M-36.9% | $51.56M-32.2% | ||
| $66.44M+13.4% | $63.14M-33.1% | $61.78M-40.4% | $55.86M-34.5% | $58.59M-30.9% | ||
| -$85K+99.4% | -$3.97M+93.4% | -$15.48M+80.4% | -$5.93M+90.0% | -$15.27M+78.4% | ||
| -0.1%+30.7pp | -5.3%+146pp | -26.5%+250pp | -10.3%+190pp | -30.8%+402pp | ||
| $15.39M-4.5% | $15.1M-13.8% | $15.8M-12.6% | $16.42M-11.7% | $16.11M-12.9% | ||
| -$13.81M+6.1% | -$13.62M+14.3% | -$14.89M+3.6% | -$15.22M-1.2% | -$14.7M+0.5% | ||
| -$13.9M+53.6% | -$17.58M+76.8% | -$30.37M+67.8% | -$21.15M+71.6% | -$29.97M+65.0% | ||
| -16.4%+44.1pp | -23.7%+168pp | -52.1%+279pp | -36.7%+214pp | -60.5%+463pp | ||
| -$0.16+61.0% | -$0.21+80.0% | -$0.37+71.8% | -$0.27+73.0% | -$0.41+68.9% | ||
| $35K+100% | -$3.85M+93.6% | -$15.37M+80.5% | -$5.8M+90.2% | -$15.12M+78.6% | ||
| 0%+30.6pp | -5.2%+146pp | -26.4%+250pp | -10.1%+190pp | -30.5%+401pp | ||
| -$85K+99.4% | -$3.97M+93.4% | -$15.48M+80.4% | -$5.93M+90.0% | -$15.27M+78.4% |
FAQ
- What is Phathom Pharmaceuticals, Inc.'s revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) generated $274.9M in revenue over the trailing twelve months, up 86.8% year over year.
- Is Phathom Pharmaceuticals, Inc. profitable?
- Phathom Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $83.0M over the trailing twelve months, a -30.2% net margin.
- What are Phathom Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 80.7% and operating margin is -9.3%, with a -30.2% net margin.
- What is Phathom Pharmaceuticals, Inc.'s earnings per share?
- Phathom Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.01.
- Where does Phathom Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
